

# Measles Post-Exposure Prophylaxis (PEP) for Non-Symptomatic Susceptible Contacts

## What is Measles PEP?

Post-exposure prophylaxis (PEP) refers to preventive treatment given after exposure to measles, in an effort to prevent or lessen illness. PEP options include:

- **MMR vaccine** (within 72 hours of exposure).
- **Immune globulin (IG)\*** via intramuscular (IGIM) or intravenous (IGIV) routes (within 6 days of exposure).

PEP is indicated only for persons who are **susceptible** (i.e., lack documented immunity). Timing and product choice depend on the patient’s age, immune status, pregnancy status, and time since first exposure.

The Minnesota Department of Health (MDH) typically identifies candidates for IG and works with healthcare systems to coordinate its use. **If you are considering IG as PEP, contact MDH for guidance at 651-201-5414 or 1-877-676-5414.**

\*Communicate with MDH regarding need for IG and measles exposure.

## Determining appropriate post-exposure prophylaxis

1. Determine patient’s risk factor and identify time from first exposure to measles case.
2. Refer to the [Reminders](#) and [Additional information](#) sections for definitions and special considerations.

Risk group	Under 72 hours	72 hours through day six from first exposure*
Infant less than 6 months old	Give intramuscular IG (IGIM): 0.5 mL/kg	Give IGIM: 0.5 mL/kg
Infant age 6 through 11 months	Give IGIM: 0.5 mL/kg or Give MMR vaccine	Give IGIM: 0.5 mL/kg
Susceptible pregnant person	Give intravenous IG (IGIV): 400 mg/kg	Give IGIV: 400 mg/kg
Severely immunocompromised	Give IGIV: 400 mg/kg	Give IGIV: 400 mg/kg
Susceptible close contact over 1 year old	Give MMR vaccine if no contraindications	Give IGIM: 0.5 mL/kg to those <66 pounds (≥66 pounds)

\*Communicate with MDH regarding need for IG and measles exposure.

## Reminders

- People at high risk for severe illness and complications from measles should be prioritized to receive immune globulin (IG). These include:
  - Infants under 12 months of age,
  - Susceptible pregnant persons, and
  - People who are severely immunocompromised (regardless of previous measles vaccination status).
- IG is not indicated for persons who have received one or more doses of measles-containing vaccine at age 12 months or older, unless they are severely immunocompromised.
- Persons do not need IGIV if:
  - They have already received or are currently receiving IGIV therapy at a dose of 400 mg/kg within three weeks before measles exposure.

- They received subcutaneous IG (IGSC) at a dose of  $\geq 200$  mg/kg for two consecutive weeks up to or through their measles exposure.

## Contraindications

- IG should not be given to people with immunoglobulin A (IgA) deficiency. Persons with IgA deficiencies have the potential for developing antibodies to IgA and therefore could experience an anaphylactic reaction when IG is administered.
- IGIM should not be administered to persons with severe thrombocytopenia or any coagulating disorder that would contraindicate intramuscular injections.
- History of anaphylactic reaction to a previous dose of IG.

## Precautions

- **Pregnancy:** It is unknown whether IG can cause fetal harm when administered to a pregnant person or if it could affect reproduction.
- **Allergy history:** IG should be administered with caution in persons with a history of systemic allergic reactions to immune globulin preparations.

## Additional information

### 1. Timing of PEP and public health monitoring:

- If PEP is given within the appropriate timeframe (within 72 hours for MMR, within six days for IG) MDH or local health department will monitor the person for symptoms through 21 days after exposure, but the person may return to school, work and activities in most situations.
- If PEP is not given or given too late (after 72 hours for MMR, on day seven or later for IG), MDH or local health department will actively monitor the person and will recommend exclusion from public places and high-risk settings such as childcare (daycare or preschool), school (including day camps), church/synagogue/mosque classes, team activities and healthcare facilities.
- There is evidence that the efficacy of either form of PEP for preventing measles disease is greatest when administered as soon as possible after exposure.

### 2. Receipt of MMR after IG or IG after MMR:

- **MMR after IG:** Any susceptible person exposed to measles who received IG should still receive MMR vaccine at the appropriate time interval noted below, provided the person is 12 months of age or older and the vaccine is not otherwise contraindicated. MMR vaccine should be administered:
  - No earlier than 6 months after IGIM administration.
  - No earlier than 8 months after IGIV administration.
- **IG after MMR:** If IG is administered within 2 weeks following the administration of MMR or varicella vaccine, the person should be revaccinated. MMR vaccine should be administered:
  - No earlier than 6 months after IGIM administration.
  - No earlier than 8 months after IGIV administration.

### 3. IGIM dosing: Intended for use in persons weighing less than 30 kg (66 lbs).

- Administer 0.5 mL/kg of intramuscular IG (IGIM) in the anterolateral aspect of the upper thigh(s). Do not follow package inserts that indicate a 0.25 mL/kg dose as this lower dose does not reflect current ACIP recommendations.

## MEASLES POST-EXPOSURE PROPHYLAXIS (PEP) FOR NON-SYMPTOMATIC SUSCEPTIBLE CONTACTS

- Do not administer more than 3mL of IGIM per injection site; for infants and children weighing >6 kg, multiple injections are required.
- The maximum total dose per IGIM administration is 15 mL.

Note: Persons weighing >30 kg (66 lbs) who receive IGIM are unlikely to receive an effective dose and will still be recommended exclusion and social distancing; IGIV can be used, but only in special situations, refer to number six.

4. **Susceptible:** PEP should only be given to a person without any evidence of immunity. Acceptable evidence of immunity (for purposes of PEP decision making) includes at least one of the following:
  - One or more documented doses of live measles virus-containing vaccine administered on or after the first birthday for children and adults who are not severely immunocompromised.
  - Laboratory evidence of immunity.
  - Birth before 1957 regardless of nationality.
  - Laboratory evidence of disease.
5. **Severely immunocompromised, includes measles contacts with:**
  - Severe primary immunodeficiency (regardless of age, vaccination status, or type of exposure).
  - Bone marrow or stem cell transplant recipients who are receiving immunosuppressive treatment, or completed treatment within past 12 months (or longer if developed graft-versus-host disease).
  - Persons currently receiving treatment for Acute Lymphocytic Leukemia (ALL) or who completed chemotherapy for ALL within previous six months.
  - Persons living with AIDS and HIV-infected persons with CD4 T-lymphocyte percent less than 15 percent (any age) or CD4 T-lymphocyte count less than 200 lymphocytes/mm<sup>3</sup> (over age 5 years), and
    - Persons who have not received MMR since starting to take Anti-Retroviral Therapy,
    - Also consider HIV-infected persons without recent confirmation of immunologic status or measles immunity.
  - Persons receiving daily corticosteroid therapy with a dose  $\geq 20$  mg (or  $> 2$  mg/kg/day for patients who weigh  $< 10$  kg) of prednisone or equivalent for  $\geq 14$  days.
  - Persons receiving certain immunomodulatory medications (e.g., tumor necrosis factor-alpha (TNF- $\alpha$ ) blockers).
6. **Susceptible close contact 12 months and older:** A susceptible contact (not pregnant or severely immunocompromised) exposed in settings with prolonged close contact (e.g., household, childcare, classroom). MDH will help determine who is a close contact. IGIV may be considered in susceptible close contacts  $\geq 66$  pounds; however, priority for IGIV should be given to susceptible pregnant person and severely immunocompromised contacts, as IGIV is expensive and difficult to administer.

Minnesota Department of Health  
PO Box 64975, St. Paul, MN 55164-0975  
651-201-5414 | [www.health.state.mn.us/immunize](http://www.health.state.mn.us/immunize)

07/15/2025

To obtain this information in a different format, call: 651-201-5414.